Wechselwirkungen von Atenolol

Atenolol (Tenormin), ein Betablocker, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 304 dokumentierte Wechselwirkungen: 12 schwerwiegende, 261 mittelschwere, 29 geringfügige und 2, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

So sieht Atenolol aus

Alle 30 Varianten
Atenolol 25 mg Tablette: weiß, rund, 6 mm, Prägung T auf der einen Seite und 107 auf der anderen.
T / 107
25 mg · weiß · rund · 6 mm
Upsher-Smith
Atenolol 100 mg Tablette: weiß, rund, 9 mm, Prägung Tenormin auf der einen Seite und 101 auf der anderen.
Tenormin / 101
100 mg · weiß · rund · 9 mm
Upsher-Smith
Atenolol 50 mg Tablette: weiß, rund, 7 mm, mit Bruchkerbe, Prägung Tenormin auf der einen Seite und 105 auf der anderen.
Tenormin / 105
50 mg · weiß · rund · 7 mm · mit Bruchkerbe
Upsher-Smith
Atenolol 25 mg Tablette: weiß, rund, 6 mm, Prägung 787 auf der einen Seite und TEVA auf der anderen.
787 / TEVA
25 mg · weiß · rund · 6 mm
Teva Pharmaceuticals

Darstellungen nach den Produktangaben der FDA-Fachinformationen: Farbe, Form, Größe und Prägung. 30 dokumentierte Varianten von 20 Anbietern.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (12)

  • ClozapinAntipsychotikumSchwerwiegend

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Fachinformation zu Clozapin, Boxed Warning (umrahmter Warnhinweis))

  • EptifibatidThrombozytenaggregationshemmerSchwerwiegend

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Fachinformation zu Eptifibatid, Gegenanzeigen)

  • FlecainidAntiarrhythmikumSchwerwiegend

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Fachinformation zu Flecainid, Boxed Warning (umrahmter Warnhinweis))

  • MetirosinSchwerwiegend

    In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Fachinformation zu Metirosin, Warnhinweise)

  • MetolazonThiaziddiuretikumSchwerwiegend

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Fachinformation zu Metolazon, Warnhinweise)

  • MinoxidilVasodilatatorSchwerwiegend

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Fachinformation zu Minoxidil, Boxed Warning (umrahmter Warnhinweis))

  • NebivololBetablockerSchwerwiegend

    Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Fachinformation zu Nebivolol, Arzneimittelwechselwirkungen)

  • ProtaminSchwerwiegend

    Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Fachinformation zu Protamin, Boxed Warning (umrahmter Warnhinweis))

  • RepaglinidGlinidSchwerwiegend

    Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

  • RivastigminCholinesterasehemmerSchwerwiegend

    Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Fachinformation zu Rivastigmin, Arzneimittelwechselwirkungen)

  • TadalafilPDE-5-HemmerSchwerwiegend

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Fachinformation zu Tadalafil, Warnhinweise und Vorsichtsmaßnahmen)

  • TranylcyprominMAO-HemmerSchwerwiegend

    …Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Fachinformation zu Tranylcypromin, Arzneimittelwechselwirkungen)

Mittelschwere Wechselwirkungen (261)

  • AcebutololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • AcetylsalicylsäureNSARMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Acetylsalicylsäure und DipyridamolThrombozytenaggregationshemmerMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AclidiniumbromidAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • AdenosinAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AdrenalinSympathomimetikumMittelschwer

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AlfuzosinAlphablockerMittelschwer

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Fachinformation zu Alfuzosin, Warnhinweise und Vorsichtsmaßnahmen)

  • AliskirenAntihypertensivumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • AlprostadilProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AmfepramonZNS-StimulansMittelschwer

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Fachinformation zu Amfepramon, Arzneimittelwechselwirkungen)

  • Amiloridkaliumsparendes DiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • AminophyllinMethylxanthinMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • AmiodaronAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AmlodipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Amlodipin und AtorvastatinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Amlodipin und BenazeprilDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • ArformoterolBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • AripiprazolAntipsychotikumMittelschwer

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Fachinformation zu Aripiprazol, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansMittelschwer

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Fachinformation zu Armodafinil, Warnhinweise und Vorsichtsmaßnahmen)

  • Articain und AdrenalinLokalanästhetikumMittelschwer

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • AsenapinAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Fachinformation zu Asenapin, Warnhinweise und Vorsichtsmaßnahmen)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • AtomoxetinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Fachinformation zu Atomoxetin, Arzneimittelwechselwirkungen)

  • AvanafilPDE-5-HemmerMittelschwer

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Fachinformation zu Avanafil, Warnhinweise und Vorsichtsmaßnahmen)

  • AzilsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • BenazeprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Benazepril und HydrochlorothiazidACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • BenzfetaminZNS-StimulansMittelschwer

    Amphetamines may decrease the hypotensive effect of antihypertensives. (Fachinformation zu Benzfetamin, Arzneimittelwechselwirkungen)

  • BetaxololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • BimatoprostProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • BisoprololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • BortezomibMittelschwer

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Fachinformation zu Bortezomib, Warnhinweise und Vorsichtsmaßnahmen)

  • BrexpiprazolAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Brexpiprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • BrimonidinAlpha-Adrenozeptor-AgonistMittelschwer

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

  • Brimonidin und TimololAlpha-Adrenozeptor-AgonistMittelschwer

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

  • BromocriptinDopaminagonistMittelschwer

    Use caution in patients taking antihypertensive medications. (Fachinformation zu Bromocriptin, Warnhinweise und Vorsichtsmaßnahmen)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Fachinformation zu Brompheniramin, Pseudoephedrin und Dextromethorphan, Arzneimittelwechselwirkungen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • BumetanidSchleifendiuretikumMittelschwer

    Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Fachinformation zu Bumetanid, Arzneimittelwechselwirkungen)

  • BupivacainLokalanästhetikumMittelschwer

    Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

  • Bupivacain und AdrenalinLokalanästhetikumMittelschwer

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • BupropionAntidepressivumMittelschwer

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (Fachinformation zu Bupropion, Arzneimittelwechselwirkungen)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • CandesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • CaptoprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • CarbidopaMittelschwer

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Fachinformation zu Carbidopa, Arzneimittelwechselwirkungen)

  • Carbidopa und Levodopadopaminerges ArzneimittelMittelschwer

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Fachinformation zu Carbidopa und Levodopa, Arzneimittelwechselwirkungen)

  • Carbidopa, Levodopa und Entacapondopaminerges ArzneimittelMittelschwer

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Fachinformation zu Carbidopa, Levodopa und Entacapon, Arzneimittelwechselwirkungen)

  • CarboprostProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • CariprazinAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Cariprazin, Warnhinweise und Vorsichtsmaßnahmen)

  • CarvedilolBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • CelecoxibNSARMittelschwer

    Intervention: • During concomitant use of VYSCOXA and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Celecoxib, Arzneimittelwechselwirkungen)

  • CevimelinCholinergikumMittelschwer

    DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Fachinformation zu Cevimelin, Arzneimittelwechselwirkungen)

  • ChinidinAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • ChlorothiazidThiaziddiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • ChlortalidonThiaziddiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • CiclosporinImmunsuppressivumMittelschwer

    If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (Fachinformation zu Ciclosporin, Vorsichtsmaßnahmen)

  • ClonidinAlpha-Adrenozeptor-AgonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • CyclobenzaprinMuskelrelaxansMittelschwer

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Fachinformation zu Cyclobenzaprin, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelMittelschwer

    …initial dosing and titration of quetiapine. e.g. perphenazine, risperidone, thioridazine ↑ antipsychotics A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with PREZISTA/ritonavir. β-Blockers : e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring of patients is recommended. (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelMittelschwer

    Initiation of quetiapine in patients taking PREZCOBIX or PREZCOBIX PED : Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. β-Blockers: e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

  • DeutetrabenazinVMAT2-HemmerMittelschwer

    Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DexmethylphenidatZNS-StimulansMittelschwer

    • Antihypertensive Drugs: Monitor blood pressure. (Fachinformation zu Dexmethylphenidat, Arzneimittelwechselwirkungen)

  • DiclofenacNSARMittelschwer

    Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Diclofenac, Arzneimittelwechselwirkungen)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DigoxinDigitalisglykosidMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DihydroergotaminMutterkornalkaloidMittelschwer

    Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Fachinformation zu Dihydroergotamin, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • DinoprostonProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DisopyramidAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DofetilidAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DoxazosinAlphablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • DronedaronAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • DuloxetinSNRIMittelschwer

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Fachinformation zu Duloxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • Dutasterid und Tamsulosin5-Alpha-ReduktasehemmerMittelschwer

    Nifedipine, Atenolol, Enalapril Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with nifedipine, atenolol, or enalapril [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Dutasterid und Tamsulosin, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Beta-Blockers: e.g., metoprolol timolol ↑ beta-blockers Clinical monitoring is recommended and a dosage decrease of the beta blocker may be necessary when these agents are coadministered with GENVOYA. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

  • EnalaprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Enalapril und HydrochlorothiazidACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • EnalaprilatACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • EplerenonAldosteronantagonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Epoetin alfaMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EpoprostenolProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Ergotamin und KoffeinMutterkornalkaloidMittelschwer

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Fachinformation zu Ergotamin und Koffein, Arzneimittelwechselwirkungen)

  • EsmololBetablockerMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • EtacrynsäureSchleifendiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • FelodipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • FenoprofenNSARMittelschwer

    Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Fachinformation zu Fenoprofen, Arzneimittelwechselwirkungen)

  • FlurbiprofenNSARMittelschwer

    Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Flurbiprofen, Arzneimittelwechselwirkungen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • FluvoxaminSSRIMittelschwer

    Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (Fachinformation zu Fluvoxamin, Arzneimittelwechselwirkungen)

  • FormoterolBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • FosinoprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Fosinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • FurosemidSchleifendiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • GlibenclamidSulfonylharnstoffMittelschwer

    …Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

  • GlimepiridSulfonylharnstoffMittelschwer

    The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

  • GlipizidSulfonylharnstoffMittelschwer

    The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

  • Glipizid und MetforminSulfonylharnstoffMittelschwer

    Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

  • GlucagonMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Antihypertensives: Possible additive hypotensive effects. (Fachinformation zu Glyceroltrinitrat (Nitroglycerin), Arzneimittelwechselwirkungen)

  • GuanfacinAlpha-Adrenozeptor-AgonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Humaninsulin (Normalinsulin)InsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes mellitus, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )], or in patients who experience recurrent hypoglycemia. (Fachinformation zu Humaninsulin (Normalinsulin), Warnhinweise und Vorsichtsmaßnahmen)

  • HydralazinVasodilatatorMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • HydrochlorothiazidThiaziddiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Hydrocodon und IbuprofenOpioidMittelschwer

    During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Hydrocodon und Ibuprofen, Arzneimittelwechselwirkungen)

  • IbuprofenNSARMittelschwer

    Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Ibuprofen, Arzneimittelwechselwirkungen)

  • Ibuprofen und FamotidinNSARMittelschwer

    Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Ibuprofen und Famotidin, Arzneimittelwechselwirkungen)

  • IbutilidAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • IloperidonAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Iloperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • IndapamidThiaziddiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • IndometacinNSARMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Insulin aspartInsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )] , or in patients who experience recurrent hypoglycemia. (Fachinformation zu Insulin aspart, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin degludecInsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )], or who experience recurrent hypoglycemia. (Fachinformation zu Insulin degludec, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin detemirInsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )], or who experience recurrent hypoglycemia. (Fachinformation zu Insulin detemir, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin glarginInsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy, using drugs that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7) ] , or who experience recurrent hypoglycemia. (Fachinformation zu Insulin glargin, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin lisproInsulinMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )] , or in patients who experience recurrent hypoglycemia. (Fachinformation zu Insulin lispro, Warnhinweise und Vorsichtsmaßnahmen)

  • IpratropiumbromidAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • Ipratropiumbromid und SalbutamolAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • IrbesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Irbesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • IsofluranAllgemeinanästhetikumMittelschwer

    Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (Fachinformation zu Isofluran, Arzneimittelwechselwirkungen)

  • IsoprenalinBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • IsradipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • ItraconazolAzol-AntimykotikumMittelschwer

    Beta Blockers Nadolol Monitor for adverse reactions. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

  • IvabradinMittelschwer

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (Fachinformation zu Ivabradin, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

  • LabetalolBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • LacosamidAntiepileptikumMittelschwer

    VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Fachinformation zu Lacosamid, Warnhinweise und Vorsichtsmaßnahmen)

  • LanreotidMittelschwer

    Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Fachinformation zu Lanreotid, Arzneimittelwechselwirkungen)

  • LatanoprostProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Ledipasvir und SofosbuvirVirostatikumMittelschwer

    Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Fachinformation zu Ledipasvir und Sofosbuvir, Warnhinweise und Vorsichtsmaßnahmen)

  • LevosalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • LevothyroxinSchilddrüsenhormonMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • Levothyroxin und LiothyroninSchilddrüsenhormonMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • LidocainLokalanästhetikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Lidocain und AdrenalinLokalanästhetikumMittelschwer

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Lidocain und PrilocainLokalanästhetikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • LiothyroninSchilddrüsenhormonMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • LisinoprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • LofexidinAlpha-Adrenozeptor-AgonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Fachinformation zu Lopinavir und Ritonavir, Warnhinweise und Vorsichtsmaßnahmen)

  • LosartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Losartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • LumateperonAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Fachinformation zu Lumateperon, Warnhinweise und Vorsichtsmaßnahmen)

  • LurasidonAntipsychotikumMittelschwer

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Fachinformation zu Lurasidon, Warnhinweise und Vorsichtsmaßnahmen)

  • MecamylaminAntihypertensivumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • MefenaminsäureNSARMittelschwer

    Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Mefenaminsäure, Arzneimittelwechselwirkungen)

  • MefloquinMalariamittelMittelschwer

    There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Fachinformation zu Mefloquin, Arzneimittelwechselwirkungen)

  • MeloxicamNSARMittelschwer

    Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Meloxicam, Arzneimittelwechselwirkungen)

  • MethyldopaAntihypertensivumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • MethylergometrinMutterkornalkaloidMittelschwer

    Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Fachinformation zu Methylergometrin, Arzneimittelwechselwirkungen)

  • MethylphenidatZNS-StimulansMittelschwer

    Antihypertensive Drugs: Monitor blood pressure. (Fachinformation zu Methylphenidat, Arzneimittelwechselwirkungen)

  • MetoprololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • MexiletinAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • MirabegronBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • MirtazapinAntidepressivumMittelschwer

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (Fachinformation zu Mirtazapin, Warnhinweise und Vorsichtsmaßnahmen)

  • MisoprostolProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • ModafinilZNS-StimulansMittelschwer

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Fachinformation zu Modafinil, Warnhinweise und Vorsichtsmaßnahmen)

  • MoexiprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • MotixafortidMittelschwer

    Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Fachinformation zu Motixafortid, Warnhinweise und Vorsichtsmaßnahmen)

  • NadololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Naltrexon und BupropionOpioidantagonistMittelschwer

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (Fachinformation zu Naltrexon und Bupropion, Arzneimittelwechselwirkungen)

  • NaproxenNSARMittelschwer

    ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Naproxen, Warnhinweise und Vorsichtsmaßnahmen)

  • Naproxen und EsomeprazolNSARMittelschwer

    Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Naproxen und Esomeprazol, Arzneimittelwechselwirkungen)

  • NateglinidGlinidMittelschwer

    Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy (nerve disease), in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)] , or in patients who experience recurrent hypoglycemia. (Fachinformation zu Nateglinid, Warnhinweise und Vorsichtsmaßnahmen)

  • NicardipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Fachinformation zu Nicotinsäure (Niacin), Arzneimittelwechselwirkungen)

  • NifedipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • NimodipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • NisoldipinDihydropyridin-CalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • NitroprussidnatriumVasodilatatorMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • OctreotidMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • OlanzapinAntipsychotikumMittelschwer

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Fachinformation zu Olanzapin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olanzapin und FluoxetinAntipsychotikumMittelschwer

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Olanzapin und Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • OlmesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • OxaprozinNSARMittelschwer

    Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Fachinformation zu Oxaprozin, Arzneimittelwechselwirkungen)

  • Oxymetazolinabschwellendes Mittel (Dekongestivum)Mittelschwer

    Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (Fachinformation zu Oxymetazolin, Arzneimittelwechselwirkungen)

  • PaliperidonAntipsychotikumMittelschwer

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Paliperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Fachinformation zu Paracetamol und Ibuprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • PasireotidMittelschwer

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Fachinformation zu Pasireotid, Warnhinweise und Vorsichtsmaßnahmen)

  • PazopanibMittelschwer

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Fachinformation zu Pazopanib, Warnhinweise und Vorsichtsmaßnahmen)

  • PentoxifyllinMethylxanthinMittelschwer

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

  • PerindoprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • PhenelzinMAO-HemmerMittelschwer

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fachinformation zu Phenelzin, Warnhinweise)

  • PhenoxybenzaminAlphablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • PilocarpinCholinergikumMittelschwer

    Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

  • PindololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

  • PiroxicamNSARMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Fachinformation zu Piroxicam, Arzneimittelwechselwirkungen)

  • PonesimodImmunsuppressivumMittelschwer

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Fachinformation zu Ponesimod, Warnhinweise und Vorsichtsmaßnahmen)

  • PrazosinAlphablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Prilocain und AdrenalinLokalanästhetikumMittelschwer

    Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • ProcainamidAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • PropafenonAntiarrhythmikumMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • PropranololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • PropylthiouracilThyreostatikumMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • PyridostigminCholinesterasehemmerMittelschwer

    Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Fachinformation zu Pyridostigmin, Warnhinweise und Vorsichtsmaßnahmen)

  • QuetiapinAntipsychotikumMittelschwer

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Quetiapin, Warnhinweise und Vorsichtsmaßnahmen)

  • QuinaprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Quinapril und HydrochlorothiazidACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • RamiprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • RifampicinAntibiotikumMittelschwer

    Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumMittelschwer

    …Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

  • RiociguatVasodilatatorMittelschwer

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Fachinformation zu Riociguat, Warnhinweise und Vorsichtsmaßnahmen)

  • RisperidonAntipsychotikumMittelschwer

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Fachinformation zu Risperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Fachinformation zu Ritonavir, Warnhinweise und Vorsichtsmaßnahmen)

  • RopivacainLokalanästhetikumMittelschwer

    Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Fachinformation zu Ropivacain, Warnhinweise und Vorsichtsmaßnahmen)

  • Sacubitril und ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • SalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • SalmeterolBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • SildenafilPDE-5-HemmerMittelschwer

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Fachinformation zu Sildenafil, Warnhinweise und Vorsichtsmaßnahmen)

  • SilodosinAlphablockerMittelschwer

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Fachinformation zu Silodosin, Warnhinweise und Vorsichtsmaßnahmen)

  • Sofosbuvir und VelpatasvirVirostatikumMittelschwer

    Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Fachinformation zu Sofosbuvir und Velpatasvir, Warnhinweise und Vorsichtsmaßnahmen)

  • SorafenibMittelschwer

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Fachinformation zu Sorafenib, Warnhinweise und Vorsichtsmaßnahmen)

  • SotalolBetablockerMittelschwer

    Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • SpironolactonAldosteronantagonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Sumatriptan und NaproxenTriptanMittelschwer

    Monitor patients to assure diuretic efficacy including antihypertensive effects. (Fachinformation zu Sumatriptan und Naproxen, Arzneimittelwechselwirkungen)

  • SunitinibMittelschwer

    Initiate and/or adjust antihypertensive therapy as appropriate. (Fachinformation zu Sunitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • TacrolimusImmunsuppressivumMittelschwer

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Fachinformation zu Tacrolimus, Warnhinweise und Vorsichtsmaßnahmen)

  • TamsulosinAlphablockerMittelschwer

    Nifedipine, Atenolol, Enalapril Dosage adjustments are not necessary when tamsulosin hydrochloride capsules are administered concomitantly with nifedipine, atenolol, or enalapril [see clinical pharmacology ( 12.3 )] . (Fachinformation zu Tamsulosin, Arzneimittelwechselwirkungen)

  • TelmisartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • Telmisartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • TerazosinAlphablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • TerbutalinBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • TeriparatidSchilddrüsenhormonMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • TestosteronAndrogenMittelschwer

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Testosteron, Warnhinweise und Vorsichtsmaßnahmen)

  • TetrabenazinVMAT2-HemmerMittelschwer

    Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • TheophyllinMethylxanthinMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • ThiamazolThyreostatikumMittelschwer

    Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

  • TiotropiumbromidAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • TizanidinMuskelrelaxansMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • TorasemidSchleifendiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • TrandolaprilACE-HemmerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • TrazodonAntidepressivumMittelschwer

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

  • TreprostinilProstaglandin-AnalogonMittelschwer

    Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • Triamterenkaliumsparendes DiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • UmeclidiniumbromidAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • Umeclidiniumbromid und VilanterolAnticholinergikumMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • ValbenazinVMAT2-HemmerMittelschwer

    Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (Fachinformation zu Atenolol, Arzneimittelwechselwirkungen)

  • ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Valsartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • VardenafilPDE-5-HemmerMittelschwer

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Fachinformation zu Vardenafil, Arzneimittelwechselwirkungen)

  • VenlafaxinSNRIMittelschwer

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Fachinformation zu Venlafaxin, Arzneimittelwechselwirkungen)

  • VerapamilCalciumkanalblockerMittelschwer

    (See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Fachinformation zu Atenolol, Warnhinweise)

  • VibegronBeta-Adrenozeptor-AgonistMittelschwer

    Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (Fachinformation zu Atenolol, Warnhinweise)

  • ZileutonCYP1A2-HemmerMittelschwer

    Zileuton increases propranolol levels and beta-blocker activity. (Fachinformation zu Zileuton, Arzneimittelwechselwirkungen)

  • ZiprasidonAntipsychotikumMittelschwer

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (29)

  • ButorphanolOpioidGeringfügig

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Fachinformation zu Butorphanol, Warnhinweise)

  • CarbamazepinAntiepileptikumGeringfügig

    CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (Fachinformation zu Carbamazepin, Arzneimittelwechselwirkungen)

  • ChlorpromazinAntipsychotikumGeringfügig

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Fachinformation zu Chlorpromazin, Warnhinweise)

  • ColestipolGallensäurebinderGeringfügig

    Effects on the absorption of other beta-blockers have not been determined. (Fachinformation zu Colestipol, Arzneimittelwechselwirkungen)

  • Desipramintrizyklisches AntidepressivumGeringfügig

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (Fachinformation zu Desipramin, Warnhinweise)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumGeringfügig

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Fachinformation zu Desogestrel und Ethinylestradiol, Warnhinweise)

  • DexamfetaminZNS-StimulansGeringfügig

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Fachinformation zu Dexamfetamin, Arzneimittelwechselwirkungen)

  • DiflunisalNSARGeringfügig

    Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Fachinformation zu Diflunisal, Arzneimittelwechselwirkungen)

  • Dorzolamid und TimololCarboanhydrasehemmerGeringfügig

    As with other beta-blockers, when discontinuation of TENORMIN is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. (Fachinformation zu Atenolol, Warnhinweise)

  • EphedrinSympathomimetikumGeringfügig

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Fachinformation zu Ephedrin, Arzneimittelwechselwirkungen)

  • EtodolacNSARGeringfügig

    Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Fachinformation zu Etodolac, Arzneimittelwechselwirkungen)

  • Finasterid5-Alpha-ReduktasehemmerGeringfügig

    …PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

  • FingolimodImmunsuppressivumGeringfügig

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fachinformation zu Fingolimod, Arzneimittelwechselwirkungen)

  • Glibenclamid und MetforminSulfonylharnstoffGeringfügig

    Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

  • IcatibantGeringfügig

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (Fachinformation zu Icatibant, Arzneimittelwechselwirkungen)

  • KetoprofenNSARGeringfügig

    ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Fachinformation zu Ketoprofen, Warnhinweise und Vorsichtsmaßnahmen)

  • KetorolacNSARGeringfügig

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (Fachinformation zu Ketorolac, Arzneimittelwechselwirkungen)

  • NabumetonNSARGeringfügig

    Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Fachinformation zu Nabumeton, Arzneimittelwechselwirkungen)

  • Nortriptylintrizyklisches AntidepressivumGeringfügig

    The antihypertensive action of guanethidine and similar agents may be blocked. (Fachinformation zu Nortriptylin, Warnhinweise)

  • PerphenazinAntipsychotikumGeringfügig

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Fachinformation zu Perphenazin, Arzneimittelwechselwirkungen)

  • ProchlorperazinAntipsychotikumGeringfügig

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (Fachinformation zu Prochlorperazin, Vorsichtsmaßnahmen)

  • Protriptylintrizyklisches AntidepressivumGeringfügig

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Fachinformation zu Protriptylin, Warnhinweise)

  • SalsalatNSARGeringfügig

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Fachinformation zu Salsalat, Arzneimittelwechselwirkungen)

  • SulindacNSARGeringfügig

    Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Fachinformation zu Sulindac, Arzneimittelwechselwirkungen)

  • TerbinafinAntimykotikumGeringfügig

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

  • TimololBetablockerGeringfügig

    As with other beta-blockers, when discontinuation of TENORMIN is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. (Fachinformation zu Atenolol, Warnhinweise)

  • TolmetinNSARGeringfügig

    DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (Fachinformation zu Tolmetin, Arzneimittelwechselwirkungen)

  • TolvaptanGeringfügig

    Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (Fachinformation zu Tolvaptan, Arzneimittelwechselwirkungen)

  • TrifluoperazinAntipsychotikumGeringfügig

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (Fachinformation zu Trifluoperazin, Vorsichtsmaßnahmen)

Keine relevante Wechselwirkung berichtet (2)

  • Atazanavirantiretrovirales ArzneimittelKeine Wechselwirkung

    Drugs with No Observed Interactions with REYATAZ No clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, atenolol, or the nucleoside reverse transcriptase inhibitors lamivudine or zidovudine [see Clinical Pharmacology, Tables 21 and 22 (12.3) ] . (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

  • SertralinSSRIKeine Wechselwirkung

    Additionally, no dosage adjustment is required for diazepam, lithium, atenolol, tolbutamide, digoxin, and drugs metabolized by CYP3A4, when sertraline hydrochloride capsules is administered concomitantly [see Clinical Pharmacology ( 12.3 )] . (Fachinformation zu Sertralin, Arzneimittelwechselwirkungen)

Prüfen Sie Atenolol gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.